Brief: GSK Announces First Positive Phase III Overall Survival Data For B7-H3-Targeted ADC In Any Tumour Type

GSK

10/07/2026 12:34

July 10 (Reuters) - GSK plc GSK.L:
GSK PLC  - HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ
GSK - ARTEMIS-8 PHASE III STUDY MEETS PRIMARY ENDPOINT IN ADVANCED OR RELAPSED SMALL-CELL LUNG CANCER
GSK - FIRST POSITIVE PHASE III OVERALL SURVIVAL DATA FOR B7-H3-TARGETED ADC IN ANY TUMOUR TYPE
GSK - RIS-REZ SHOWS SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL VERSUS STANDARD OF CARE
GSK - CONSISTENT BENEFIT OBSERVED ACROSS KEY SECONDARY ENDPOINTS INCLUDING PROGRESSION-FREE SURVIVAL
GSK - EXPECTS PIVOTAL DATA FROM EMBOLD SCLC-301 PHASE III TRIAL NEXT YEAR
Source text: ID:nRSJ9284La
Further company coverage: GSK.L

 ((Reuters.Briefs@thomsonreuters.com;))